ONMD

SEC source: 0001493152-25-025279 · ownership.xml · nonDerivative · entry 10

Yu Jeffrey · CIK 0001991132 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,004,824

F9 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.79 to $0.85, inclusive.

SEC source: 0001493152-25-025277 · ownership.xml · nonDerivative · entry 8

Kosasa Thomas · CIK 0001989846 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,734,191

F6 · shares: On August 29, 2025, the issuer entered into a subscription agreement with the reporting person, pursuant to which the issuer agreed to sell 581,395 shares of common stock to the reporting person at a purchase price of $0.86 per share, totaling $500,000 in gross proceeds to the issuer.

SEC source: 0001493152-25-025279 · ownership.xml · nonDerivative · entry 9

Yu Jeffrey · CIK 0001991132 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,993,934

F8 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.78 to $0.81, inclusive.

SEC source: 0001493152-25-025279 · ownership.xml · nonDerivative · entry 8

Yu Jeffrey · CIK 0001991132 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,976,934

F7 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.68 to $0.72, inclusive.

SEC source: 0001493152-25-025279 · ownership.xml · nonDerivative · entry 7

Yu Jeffrey · CIK 0001991132 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,955,560

F6 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.66 to $0.79, inclusive.

SEC source: 0001493152-25-025279 · ownership.xml · nonDerivative · entry 6

Yu Jeffrey · CIK 0001991132 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,782,210

F5 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.74 to $0.75, inclusive.

SEC source: 0001493152-25-025279 · ownership.xml · nonDerivative · entry 5

Yu Jeffrey · CIK 0001991132 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,768,910

SEC source: 0001493152-25-025279 · ownership.xml · nonDerivative · entry 4

Yu Jeffrey · CIK 0001991132 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,753,910

F4 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.76 to $0.79, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in the footnotes of this report.

SEC source: 0001493152-25-025279 · ownership.xml · nonDerivative · entry 3

Yu Jeffrey · CIK 0001991132 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,737,410

F3 · shares: On June 20, 2025, the issuer entered into a subscription agreement with the reporting person, pursuant which the issuer agreed to sell 1,666,666 shares of common stock to the reporting person at a purchase price of $0.42 per share, totaling $700,000 in gross proceeds to the issuer.

SEC source: 0001493152-25-025277 · ownership.xml · nonDerivative · entry 7

Kosasa Thomas · CIK 0001989846 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,152,796

F5 · shares: On June 20, 2025, the issuer entered into a subscription agreement with the reporting person, pursuant which the issuer agreed to sell 1,190,476 shares of common stock to the reporting person at a purchase price of $0.42 per share, totaling $500,000 in gross proceeds to the issuer.

SEC source: 0001493152-25-025279 · ownership.xml · nonDerivative · entry 2

Yu Jeffrey · CIK 0001991132 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,070,744

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · shares: On June 19, 2025, the issuer entered into an agreement with the reporting person to convert an aggregate of approximately $1.3 million of outstanding principal and accrued interest under certain shareholder loans and business combination extension loans.

SEC source: 0001493152-25-025277 · ownership.xml · nonDerivative · entry 6

Kosasa Thomas · CIK 0001989846 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,962,320

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · shares: On June 19, 2025, the issuer entered into an agreement with the reporting person to convert an aggregate of approximately $2.0 million of outstanding principal and accrued interest under certain shareholder loans and business combination extension loans.

SEC source: 0001493152-25-025277 · ownership.xml · nonDerivative · entry 5

Kosasa Thomas · CIK 0001989846 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,097,304

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · shares: On June 19, 2025, the reporting person delivered notice of his election to convert in full the amounts of outstanding principal under certain convertible shareholder loans previously made by the reporting person to the issuer, in an aggregate principal amount of approximately $1.6 million.

SEC source: 0001493152-25-025279 · ownership.xml · derivative · entry 24

Yu Jeffrey · CIK 0001991132 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 479,270 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On June 28, 2023, Data Knights Acquisition Corp. ("Data Knights") (the predecessor of the issuer) and certain investors, including the reporting person (collectively, the "Purchasers"), entered into a securities purchase agreement pursuant to which Data Knights issued and sold to the Purchasers senior secured convertible notes (the "PIPE Notes"), which are convertible into shares of common stock at each Purchasers' election, at a conversion price equal to the lower of (i) $10.00 per share, or (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) trading days immediately preceding the conversion date, subject to a floor price of $1.14. The PIPE Notes matured on the first anniversary of the issuance date (November 7, 2024), subject to extension pursuant to the terms of the PIPE Notes. The conversion shares included accrued interest from the date of issuance.

F1 · price: On June 28, 2023, Data Knights Acquisition Corp. ("Data Knights") (the predecessor of the issuer) and certain investors, including the reporting person (collectively, the "Purchasers"), entered into a securities purchase agreement pursuant to which Data Knights issued and sold to the Purchasers senior secured convertible notes (the "PIPE Notes"), which are convertible into shares of common stock at each Purchasers' election, at a conversion price equal to the lower of (i) $10.00 per share, or (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) trading days immediately preceding the conversion date, subject to a floor price of $1.14. The PIPE Notes matured on the first anniversary of the issuance date (November 7, 2024), subject to extension pursuant to the terms of the PIPE Notes. The conversion shares included accrued interest from the date of issuance.

F1 · derivative.exercise_date: On June 28, 2023, Data Knights Acquisition Corp. ("Data Knights") (the predecessor of the issuer) and certain investors, including the reporting person (collectively, the "Purchasers"), entered into a securities purchase agreement pursuant to which Data Knights issued and sold to the Purchasers senior secured convertible notes (the "PIPE Notes"), which are convertible into shares of common stock at each Purchasers' election, at a conversion price equal to the lower of (i) $10.00 per share, or (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) trading days immediately preceding the conversion date, subject to a floor price of $1.14. The PIPE Notes matured on the first anniversary of the issuance date (November 7, 2024), subject to extension pursuant to the terms of the PIPE Notes. The conversion shares included accrued interest from the date of issuance.

F1 · derivative.expiration_date: On June 28, 2023, Data Knights Acquisition Corp. ("Data Knights") (the predecessor of the issuer) and certain investors, including the reporting person (collectively, the "Purchasers"), entered into a securities purchase agreement pursuant to which Data Knights issued and sold to the Purchasers senior secured convertible notes (the "PIPE Notes"), which are convertible into shares of common stock at each Purchasers' election, at a conversion price equal to the lower of (i) $10.00 per share, or (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) trading days immediately preceding the conversion date, subject to a floor price of $1.14. The PIPE Notes matured on the first anniversary of the issuance date (November 7, 2024), subject to extension pursuant to the terms of the PIPE Notes. The conversion shares included accrued interest from the date of issuance.

F8 · derivative.underlying_shares: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.78 to $0.81, inclusive.

SEC source: 0001493152-25-025279 · ownership.xml · nonDerivative · entry 1

Yu Jeffrey · CIK 0001991132 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,242,465

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On June 28, 2023, Data Knights Acquisition Corp. ("Data Knights") (the predecessor of the issuer) and certain investors, including the reporting person (collectively, the "Purchasers"), entered into a securities purchase agreement pursuant to which Data Knights issued and sold to the Purchasers senior secured convertible notes (the "PIPE Notes"), which are convertible into shares of common stock at each Purchasers' election, at a conversion price equal to the lower of (i) $10.00 per share, or (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) trading days immediately preceding the conversion date, subject to a floor price of $1.14. The PIPE Notes matured on the first anniversary of the issuance date (November 7, 2024), subject to extension pursuant to the terms of the PIPE Notes. The conversion shares included accrued interest from the date of issuance.

SEC source: 0001493152-25-025276 · ownership.xml · derivative · entry 5

Green Aaron · CIK 0001990275 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 240,425 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: On June 28, 2023, Data Knights Acquisition Corp. ("Data Knights") (the predecessor of the issuer) and certain investors, including the reporting person (collectively, the "Purchasers"), entered into a securities purchase agreement pursuant to which Data Knights issued and sold to the Purchasers senior secured convertible notes (the "PIPE Notes"), which are convertible into shares of common stock at each Purchasers' election, at a conversion price equal to the lower of (i) $10.00 per share, or (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) trading days immediately preceding the conversion date, subject to a floor price of $1.14. The PIPE Notes matured on the first anniversary of the issuance date (November 7, 2024), subject to extension pursuant to the terms of the PIPE Notes. The conversion shares included accrued interest from the date of issuance.

F2 · price: On June 28, 2023, Data Knights Acquisition Corp. ("Data Knights") (the predecessor of the issuer) and certain investors, including the reporting person (collectively, the "Purchasers"), entered into a securities purchase agreement pursuant to which Data Knights issued and sold to the Purchasers senior secured convertible notes (the "PIPE Notes"), which are convertible into shares of common stock at each Purchasers' election, at a conversion price equal to the lower of (i) $10.00 per share, or (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) trading days immediately preceding the conversion date, subject to a floor price of $1.14. The PIPE Notes matured on the first anniversary of the issuance date (November 7, 2024), subject to extension pursuant to the terms of the PIPE Notes. The conversion shares included accrued interest from the date of issuance.

F2 · derivative.exercise_date: On June 28, 2023, Data Knights Acquisition Corp. ("Data Knights") (the predecessor of the issuer) and certain investors, including the reporting person (collectively, the "Purchasers"), entered into a securities purchase agreement pursuant to which Data Knights issued and sold to the Purchasers senior secured convertible notes (the "PIPE Notes"), which are convertible into shares of common stock at each Purchasers' election, at a conversion price equal to the lower of (i) $10.00 per share, or (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) trading days immediately preceding the conversion date, subject to a floor price of $1.14. The PIPE Notes matured on the first anniversary of the issuance date (November 7, 2024), subject to extension pursuant to the terms of the PIPE Notes. The conversion shares included accrued interest from the date of issuance.

F2 · derivative.expiration_date: On June 28, 2023, Data Knights Acquisition Corp. ("Data Knights") (the predecessor of the issuer) and certain investors, including the reporting person (collectively, the "Purchasers"), entered into a securities purchase agreement pursuant to which Data Knights issued and sold to the Purchasers senior secured convertible notes (the "PIPE Notes"), which are convertible into shares of common stock at each Purchasers' election, at a conversion price equal to the lower of (i) $10.00 per share, or (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) trading days immediately preceding the conversion date, subject to a floor price of $1.14. The PIPE Notes matured on the first anniversary of the issuance date (November 7, 2024), subject to extension pursuant to the terms of the PIPE Notes. The conversion shares included accrued interest from the date of issuance.

F2 · derivative.underlying_shares: On June 28, 2023, Data Knights Acquisition Corp. ("Data Knights") (the predecessor of the issuer) and certain investors, including the reporting person (collectively, the "Purchasers"), entered into a securities purchase agreement pursuant to which Data Knights issued and sold to the Purchasers senior secured convertible notes (the "PIPE Notes"), which are convertible into shares of common stock at each Purchasers' election, at a conversion price equal to the lower of (i) $10.00 per share, or (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) trading days immediately preceding the conversion date, subject to a floor price of $1.14. The PIPE Notes matured on the first anniversary of the issuance date (November 7, 2024), subject to extension pursuant to the terms of the PIPE Notes. The conversion shares included accrued interest from the date of issuance.

SEC source: 0001493152-25-025276 · ownership.xml · nonDerivative · entry 2

Green Aaron · CIK 0001990275 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 885,425

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · shares: On June 28, 2023, Data Knights Acquisition Corp. ("Data Knights") (the predecessor of the issuer) and certain investors, including the reporting person (collectively, the "Purchasers"), entered into a securities purchase agreement pursuant to which Data Knights issued and sold to the Purchasers senior secured convertible notes (the "PIPE Notes"), which are convertible into shares of common stock at each Purchasers' election, at a conversion price equal to the lower of (i) $10.00 per share, or (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) trading days immediately preceding the conversion date, subject to a floor price of $1.14. The PIPE Notes matured on the first anniversary of the issuance date (November 7, 2024), subject to extension pursuant to the terms of the PIPE Notes. The conversion shares included accrued interest from the date of issuance.

SEC source: 0001493152-25-025277 · ownership.xml · derivative · entry 11

Kosasa Thomas · CIK 0001989846 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 493,056 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: On June 28, 2023, Data Knights Acquisition Corp. ("Data Knights") (the predecessor of the issuer) and certain investors, including the reporting person (collectively, the "Purchasers"), entered into a securities purchase agreement pursuant to which Data Knights issued and sold to the Purchasers senior secured convertible notes (the "PIPE Notes"), which are convertible into shares of common stock at each Purchasers' election, at a conversion price equal to the lower of (i) $10.00 per share, or (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) trading days immediately preceding the conversion date, subject to a floor price of $1.14. The PIPE Notes matured on the first anniversary of the issuance date (November 7, 2024), subject to extension pursuant to the terms of the PIPE Notes. The conversion shares included accrued interest from the date of issuance.

F2 · price: On June 28, 2023, Data Knights Acquisition Corp. ("Data Knights") (the predecessor of the issuer) and certain investors, including the reporting person (collectively, the "Purchasers"), entered into a securities purchase agreement pursuant to which Data Knights issued and sold to the Purchasers senior secured convertible notes (the "PIPE Notes"), which are convertible into shares of common stock at each Purchasers' election, at a conversion price equal to the lower of (i) $10.00 per share, or (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) trading days immediately preceding the conversion date, subject to a floor price of $1.14. The PIPE Notes matured on the first anniversary of the issuance date (November 7, 2024), subject to extension pursuant to the terms of the PIPE Notes. The conversion shares included accrued interest from the date of issuance.

F2 · derivative.exercise_date: On June 28, 2023, Data Knights Acquisition Corp. ("Data Knights") (the predecessor of the issuer) and certain investors, including the reporting person (collectively, the "Purchasers"), entered into a securities purchase agreement pursuant to which Data Knights issued and sold to the Purchasers senior secured convertible notes (the "PIPE Notes"), which are convertible into shares of common stock at each Purchasers' election, at a conversion price equal to the lower of (i) $10.00 per share, or (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) trading days immediately preceding the conversion date, subject to a floor price of $1.14. The PIPE Notes matured on the first anniversary of the issuance date (November 7, 2024), subject to extension pursuant to the terms of the PIPE Notes. The conversion shares included accrued interest from the date of issuance.

F2 · derivative.expiration_date: On June 28, 2023, Data Knights Acquisition Corp. ("Data Knights") (the predecessor of the issuer) and certain investors, including the reporting person (collectively, the "Purchasers"), entered into a securities purchase agreement pursuant to which Data Knights issued and sold to the Purchasers senior secured convertible notes (the "PIPE Notes"), which are convertible into shares of common stock at each Purchasers' election, at a conversion price equal to the lower of (i) $10.00 per share, or (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) trading days immediately preceding the conversion date, subject to a floor price of $1.14. The PIPE Notes matured on the first anniversary of the issuance date (November 7, 2024), subject to extension pursuant to the terms of the PIPE Notes. The conversion shares included accrued interest from the date of issuance.

F2 · derivative.underlying_shares: On June 28, 2023, Data Knights Acquisition Corp. ("Data Knights") (the predecessor of the issuer) and certain investors, including the reporting person (collectively, the "Purchasers"), entered into a securities purchase agreement pursuant to which Data Knights issued and sold to the Purchasers senior secured convertible notes (the "PIPE Notes"), which are convertible into shares of common stock at each Purchasers' election, at a conversion price equal to the lower of (i) $10.00 per share, or (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) trading days immediately preceding the conversion date, subject to a floor price of $1.14. The PIPE Notes matured on the first anniversary of the issuance date (November 7, 2024), subject to extension pursuant to the terms of the PIPE Notes. The conversion shares included accrued interest from the date of issuance.

SEC source: 0001493152-25-025277 · ownership.xml · nonDerivative · entry 4

Kosasa Thomas · CIK 0001989846 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,973,880

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · shares: On June 28, 2023, Data Knights Acquisition Corp. ("Data Knights") (the predecessor of the issuer) and certain investors, including the reporting person (collectively, the "Purchasers"), entered into a securities purchase agreement pursuant to which Data Knights issued and sold to the Purchasers senior secured convertible notes (the "PIPE Notes"), which are convertible into shares of common stock at each Purchasers' election, at a conversion price equal to the lower of (i) $10.00 per share, or (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) trading days immediately preceding the conversion date, subject to a floor price of $1.14. The PIPE Notes matured on the first anniversary of the issuance date (November 7, 2024), subject to extension pursuant to the terms of the PIPE Notes. The conversion shares included accrued interest from the date of issuance.

SEC source: 0001493152-25-025277 · ownership.xml · nonDerivative · entry 3

Kosasa Thomas · CIK 0001989846 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,480,824

SEC source: 0001493152-25-025279 · ownership.xml · derivative · entry 25

Yu Jeffrey · CIK 0001991132 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,946

Underlying: Common Stock · 5,946 shares

Expires 2028-11-07

SEC source: 0001493152-25-025277 · ownership.xml · nonDerivative · entry 2

Kosasa Thomas · CIK 0001989846 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,425,824

SEC source: 0001493152-25-025275 · ownership.xml · nonDerivative · entry 4

Golden Robert Lawrence · CIK 0001585507 · Director · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 169,572

F3 · shares: Represents RSUs granted in lieu of a cash bonus pursuant to contractor arrangements with the reporting person in connection with his appointment as permanent Chief Financial Officer. The RSUs fully vested on the grant date.

SEC source: 0001493152-25-025271 · ownership.xml · nonDerivative · entry 2

Clarke Jair · CIK 0001939502 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,485

F2 · shares: Represents RSUs granted as director compensation under the 2022 Plan for service on the Commercial Committee. The RSUs vest as follows: (i) 50% of the RSU vest quarterly on the last day of each quarter for the applicable calendar year, subject to the reporting person's continued service with the issuer through each vesting date (the "Time Vesting Schedule"), and (ii) 50% of the RSUs vest on the Time Vesting Schedule if the issuer's revenue exceeds a specific threshold determined by the Board of Directors.

SEC source: 0001493152-25-025273 · ownership.xml · nonDerivative · entry 2

Zeinfeld Andrew B · CIK 0001361934 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 336,525

F2 · shares: Represents RSUs granted as director compensation under the 2022 Plan for service on the Commercial Committee. The RSUs vest as follows: (i) 50% of the RSU vest quarterly on the last day of each quarter for the applicable calendar year, subject to the reporting person's continued service with the issuer through each vesting date (the "Time Vesting Schedule"), and (ii) 50% of the RSUs vest on the Time Vesting Schedule if the issuer's revenue exceeds a specific threshold determined by the Board of Directors.

SEC source: 0001493152-25-025278 · ownership.xml · nonDerivative · entry 22

Yu Jeffrey · CIK 0001991132 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,763,195

SEC source: 0001493152-25-025274 · ownership.xml · nonDerivative · entry 7

Casaburi Eric · CIK 0001990853 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,475

SEC source: 0001493152-25-025274 · ownership.xml · nonDerivative · entry 6

Casaburi Eric · CIK 0001990853 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,175

SEC source: 0001493152-25-025278 · ownership.xml · nonDerivative · entry 21

Yu Jeffrey · CIK 0001991132 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,763,095

F12 · shares: Represents restricted stock units ("RSUs") issued in lieu of cash compensation, which RSUs vested in full on July 1, 2025. Each RSU represents the contingent right to receive one share of the issuer's common stock.

SEC source: 0001493152-25-025272 · ownership.xml · nonDerivative · entry 1

McCraw Sherry Coonse · CIK 0002084961 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,342

F1 · shares: Represents restricted stock units ("RSUs") granted as director compensation under the OneMedNet Corporation 2022 Equity Incentive Plan (the "2022 Plan") for board service in fiscal year 2024. Each RSU represents the contingent right to receive one share of the issuer's common stock. The RSUs vested on December 31, 2024.

SEC source: 0001493152-25-025271 · ownership.xml · nonDerivative · entry 1

Clarke Jair · CIK 0001939502 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,342

F1 · shares: Represents restricted stock units ("RSUs") granted as director compensation under the OneMedNet Corporation 2022 Equity Incentive Plan (the "2022 Plan") for board service in fiscal year 2024. Each RSU represents the contingent right to receive one share of the issuer's common stock. The RSUs vested on December 31, 2024.

SEC source: 0001493152-25-025278 · ownership.xml · nonDerivative · entry 20

Yu Jeffrey · CIK 0001991132 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,532,326

F11 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.62 to $0.66, inclusive.

SEC source: 0001493152-25-025278 · ownership.xml · nonDerivative · entry 19

Yu Jeffrey · CIK 0001991132 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,530,726

F10 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.65 to $0.71, inclusive.

SEC source: 0001493152-25-025275 · ownership.xml · nonDerivative · entry 3

Golden Robert Lawrence · CIK 0001585507 · Director · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 145,300

F2 · shares: Represents RSUs granted pursuant to a consulting agreement with the reporting person. The RSUs vested on August 30, 2025.

SEC source: 0001493152-25-025278 · ownership.xml · nonDerivative · entry 18

Yu Jeffrey · CIK 0001991132 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,529,926

SEC source: 0001493152-25-025278 · ownership.xml · nonDerivative · entry 17

Yu Jeffrey · CIK 0001991132 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,529,826

F9 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.36 to $1.46, inclusive.

SEC source: 0001493152-25-025278 · ownership.xml · nonDerivative · entry 16

Yu Jeffrey · CIK 0001991132 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,529,812

SEC source: 0001493152-25-025278 · ownership.xml · nonDerivative · entry 15

Yu Jeffrey · CIK 0001991132 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,529,802

F8 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.33 to $1.37, inclusive.

SEC source: 0001493152-25-025273 · ownership.xml · nonDerivative · entry 1

Zeinfeld Andrew B · CIK 0001361934 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 254,382

F1 · shares: Represents restricted stock units ("RSUs") granted as director compensation under the OneMedNet Corporation 2022 Equity Incentive Plan (the "2022 Plan") for board service in fiscal year 2024. Each RSU represents the contingent right to receive one share of the issuer's common stock. The RSUs vested on December 31, 2024.

SEC source: 0001493152-25-025278 · ownership.xml · nonDerivative · entry 14

Yu Jeffrey · CIK 0001991132 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,529,789

F7 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.16 to $1.25, inclusive.

SEC source: 0001493152-25-025278 · ownership.xml · nonDerivative · entry 13

Yu Jeffrey · CIK 0001991132 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,527,552

F6 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.06 to $1.16, inclusive.

SEC source: 0001493152-25-025274 · ownership.xml · nonDerivative · entry 5

Casaburi Eric · CIK 0001990853 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,675

SEC source: 0001493152-25-025278 · ownership.xml · nonDerivative · entry 12

Yu Jeffrey · CIK 0001991132 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,526,639

F5 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.50 to $0.55, inclusive.

SEC source: 0001493152-25-025278 · ownership.xml · nonDerivative · entry 11

Yu Jeffrey · CIK 0001991132 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,525,436

SEC source: 0001493152-25-025278 · ownership.xml · nonDerivative · entry 10

Yu Jeffrey · CIK 0001991132 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,525,331

F4 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.66 to $0.69, inclusive.

SEC source: 0001493152-25-025278 · ownership.xml · nonDerivative · entry 9

Yu Jeffrey · CIK 0001991132 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,525,225

F3 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.61 to $0.67, inclusive.

SEC source: 0001493152-25-025278 · ownership.xml · nonDerivative · entry 8

Yu Jeffrey · CIK 0001991132 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,525,011

F2 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.59 to $0.61, inclusive.

SEC source: 0001493152-25-025278 · ownership.xml · nonDerivative · entry 7

Yu Jeffrey · CIK 0001991132 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,524,661

SEC source: 0001493152-25-025278 · ownership.xml · nonDerivative · entry 6

Yu Jeffrey · CIK 0001991132 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,524,561

SEC source: 0001493152-25-025278 · ownership.xml · nonDerivative · entry 5

Yu Jeffrey · CIK 0001991132 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,524,461